Panel Discussion: Incorporating Industry Perspectives When Examining Existing & Evolving Endpoints – “Feels, Functions, Survives”

Time: 9:45 am
day: Day One


• Exploring the industry’s interpretations of Feels, Functions, Survives and the practical considerations and implications on drug development

• What is it going to take for the regulators to see beyond FVC and how can we as the industry precompetitive and come together to action this

• What additional surrogates of mortality are available, can we infer these from other diseases?

• Highlighting the importance of collaboration between researchers, regulators, clinicians, and patient advocates to drive the adoption of patient-centred endpoints